DE2131626A1 - 3,4,5-Dialkoxy-hydroxybenzoylaminoalkancarbonsaeuren und ihre Salze sowie Arzneipraeparate - Google Patents
3,4,5-Dialkoxy-hydroxybenzoylaminoalkancarbonsaeuren und ihre Salze sowie ArzneipraeparateInfo
- Publication number
- DE2131626A1 DE2131626A1 DE19712131626 DE2131626A DE2131626A1 DE 2131626 A1 DE2131626 A1 DE 2131626A1 DE 19712131626 DE19712131626 DE 19712131626 DE 2131626 A DE2131626 A DE 2131626A DE 2131626 A1 DE2131626 A1 DE 2131626A1
- Authority
- DE
- Germany
- Prior art keywords
- salts
- dialkoxy
- acid
- acids
- hydroxybenzoylaminoalkanecarboxylic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002253 acid Substances 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- 150000007513 acids Chemical class 0.000 title claims description 5
- 150000003839 salts Chemical class 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 208000010125 myocardial infarction Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000006793 arrhythmia Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 229960002684 aminocaproic acid Drugs 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- RXQNHIDQIJXKTK-UHFFFAOYSA-N azane;pentanoic acid Chemical compound [NH4+].CCCCC([O-])=O RXQNHIDQIJXKTK-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940072644 pitressin Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5032870A | 1970-06-26 | 1970-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2131626A1 true DE2131626A1 (de) | 1971-12-30 |
Family
ID=21964620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712131626 Pending DE2131626A1 (de) | 1970-06-26 | 1971-06-25 | 3,4,5-Dialkoxy-hydroxybenzoylaminoalkancarbonsaeuren und ihre Salze sowie Arzneipraeparate |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3769335A (cg-RX-API-DMAC10.html) |
| BE (1) | BE768812A (cg-RX-API-DMAC10.html) |
| CA (1) | CA919699A (cg-RX-API-DMAC10.html) |
| DE (1) | DE2131626A1 (cg-RX-API-DMAC10.html) |
| FR (1) | FR2100830B1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB1319197A (cg-RX-API-DMAC10.html) |
| IL (1) | IL37140A0 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA714115B (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011845A3 (de) * | 1978-11-30 | 1981-05-06 | Henkel Kommanditgesellschaft auf Aktien | Haarbehandlungsmittel mit Antischuppenwirkung |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271192A (en) * | 1980-02-19 | 1981-06-02 | Massachusetts Institute Of Technology | Process for treatment and prevention of ventricular fibrillation |
| DE3042482A1 (de) * | 1980-11-11 | 1982-06-24 | A. Nattermann & Cie GmbH, 5000 Köln | N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| JPS57140754A (en) * | 1981-02-24 | 1982-08-31 | Kureha Chem Ind Co Ltd | Dihydroxybenzoic acid derivative and physiologically active preparation containing the same |
-
1970
- 1970-06-26 US US00050328A patent/US3769335A/en not_active Expired - Lifetime
-
1971
- 1971-05-10 CA CA112590A patent/CA919699A/en not_active Expired
- 1971-05-27 GB GB1770271A patent/GB1319197A/en not_active Expired
- 1971-06-21 BE BE768812A patent/BE768812A/xx unknown
- 1971-06-23 ZA ZA714115A patent/ZA714115B/xx unknown
- 1971-06-24 IL IL37140A patent/IL37140A0/xx unknown
- 1971-06-25 DE DE19712131626 patent/DE2131626A1/de active Pending
- 1971-06-25 FR FR7123319A patent/FR2100830B1/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011845A3 (de) * | 1978-11-30 | 1981-05-06 | Henkel Kommanditgesellschaft auf Aktien | Haarbehandlungsmittel mit Antischuppenwirkung |
Also Published As
| Publication number | Publication date |
|---|---|
| BE768812A (fr) | 1971-11-03 |
| ZA714115B (en) | 1972-03-29 |
| GB1319197A (en) | 1973-06-06 |
| IL37140A0 (en) | 1971-08-25 |
| US3769335A (en) | 1973-10-30 |
| FR2100830A1 (cg-RX-API-DMAC10.html) | 1972-03-24 |
| CA919699A (en) | 1973-01-23 |
| FR2100830B1 (cg-RX-API-DMAC10.html) | 1974-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2856393C2 (de) | Arzneimittel zur Behandlung von Morbus Parkinson | |
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE2528360A1 (de) | Neue pyrimidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen | |
| DE1802394C2 (de) | Arzneimittel mit antihypertensiver Wirkung, die [(2,6-Dichlorbenzyliden)-amino]-guanidin oder ein Säureadditionssalz davon enthalten | |
| DE3415394A1 (de) | Medikament gegen ovarialinsuffizienz | |
| DE2359128A1 (de) | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE3779842T2 (de) | Antiallergisches mittel. | |
| EP0571457B1 (de) | Iloprost mit wirkung gegen cerebrale malaria | |
| DE2131626A1 (de) | 3,4,5-Dialkoxy-hydroxybenzoylaminoalkancarbonsaeuren und ihre Salze sowie Arzneipraeparate | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| DE1900772C3 (de) | Salz aus N,N-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel | |
| DE3880564T2 (de) | Arzneimittel zur behandlung von herzinsuffizienz. | |
| DE2131680A1 (de) | 3,4,5-Trialkoxybenzoylaminoalkancarbonsaeure-Verbindungen und ihre Salze sowie Arzneipraeparate | |
| DE2416339C3 (de) | Argininpyroglutaniat, Verfahren zu seiner Herstellung und Arzneimittel | |
| DE2755016C2 (cg-RX-API-DMAC10.html) | ||
| DE2131674A1 (de) | 3,4,5-Trialkoxybenzoylaminoalkancarbonsaeuren und ihre Salze sowie Arzneipraeparate | |
| DE2525064A1 (de) | Arzneimittel und verfahren zu seiner herstellung | |
| DE2038628B2 (de) | N,N'-Di(carboxyalkyl)-p-phenylendiamine, deren Salze und Diäthylester, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2131676A1 (de) | 3,4,5-Trialkoxybenzoyl-alkancarbonsaeuren und ihre Salze sowie Arzneipraeparate | |
| DE2820808A1 (de) | Arzneimittel mit einer antanginoesen wirksamkeit | |
| DE2131677A1 (de) | 3,4,5-Trialkoxyphenylalkancarbonsaeuren und ihre Salze sowie Arzneipraeparate | |
| DE2030932C3 (de) | Arzneimittel zur oralen Behandlung von Oxalatsteinen | |
| DE60311134T2 (de) | Oromukosale formulierung und herstellungsverfahren dafür | |
| DE2131675A1 (de) | 3,4,5-Trialkoxybenzoylaminocarbonsaeuren und ihre Salze sowie Arzneipraeparate |